210 related articles for article (PubMed ID: 18378677)
21. Purification and cloning of PZR, a binding protein and putative physiological substrate of tyrosine phosphatase SHP-2.
Zhao ZJ; Zhao R
J Biol Chem; 1998 Nov; 273(45):29367-72. PubMed ID: 9792637
[TBL] [Abstract][Full Text] [Related]
22. Shp-2 specifically regulates several tyrosine-phosphorylated proteins in brain-derived neurotrophic factor signaling in cultured cerebral cortical neurons.
Araki T; Yamada M; Ohnishi H; Sano S; Uetsuki T; Hatanaka H
J Neurochem; 2000 Feb; 74(2):659-68. PubMed ID: 10646517
[TBL] [Abstract][Full Text] [Related]
23. Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling.
Yu WM; Daino H; Chen J; Bunting KD; Qu CK
J Biol Chem; 2006 Mar; 281(9):5426-34. PubMed ID: 16371368
[TBL] [Abstract][Full Text] [Related]
24. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
Kontaridis MI; Swanson KD; David FS; Barford D; Neel BG
J Biol Chem; 2006 Mar; 281(10):6785-92. PubMed ID: 16377799
[TBL] [Abstract][Full Text] [Related]
25. Integrin-mediated tyrosine phosphorylation of SHPS-1 and its association with SHP-2. Roles of Fak and Src family kinases.
Tsuda M; Matozaki T; Fukunaga K; Fujioka Y; Imamoto A; Noguchi T; Takada T; Yamao T; Takeda H; Ochi F; Yamamoto T; Kasuga M
J Biol Chem; 1998 May; 273(21):13223-9. PubMed ID: 9582366
[TBL] [Abstract][Full Text] [Related]
26. Blocking the function of tyrosine phosphatase SHP-2 by targeting its Src homology 2 domains.
Zhao R; Fu X; Teng L; Li Q; Zhao ZJ
J Biol Chem; 2003 Oct; 278(44):42893-8. PubMed ID: 12913007
[TBL] [Abstract][Full Text] [Related]
27. The tyrosine phosphatase Shp-2 interacts with the dopamine D(1) receptor and triggers D(1) -mediated Erk signaling in striatal neurons.
Fiorentini C; Mattanza C; Collo G; Savoia P; Spano P; Missale C
J Neurochem; 2011 Apr; 117(2):253-63. PubMed ID: 21272002
[TBL] [Abstract][Full Text] [Related]
28. A suggested role for mitochondria in Noonan syndrome.
Lee I; Pecinova A; Pecina P; Neel BG; Araki T; Kucherlapati R; Roberts AE; Hüttemann M
Biochim Biophys Acta; 2010 Feb; 1802(2):275-83. PubMed ID: 19835954
[TBL] [Abstract][Full Text] [Related]
29. Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature.
Siegfried A; Cances C; Denuelle M; Loukh N; Tauber M; Cavé H; Delisle MB
Am J Med Genet A; 2017 Apr; 173(4):1061-1065. PubMed ID: 28328117
[TBL] [Abstract][Full Text] [Related]
30. Signal regulatory protein alpha ligation induces macrophage nitric oxide production through JAK/STAT- and phosphatidylinositol 3-kinase/Rac1/NAPDH oxidase/H2O2-dependent pathways.
Alblas J; Honing H; de Lavalette CR; Brown MH; Dijkstra CD; van den Berg TK
Mol Cell Biol; 2005 Aug; 25(16):7181-92. PubMed ID: 16055727
[TBL] [Abstract][Full Text] [Related]
31. Germ-line and somatic PTPN11 mutations in human disease.
Tartaglia M; Gelb BD
Eur J Med Genet; 2005; 48(2):81-96. PubMed ID: 16053901
[TBL] [Abstract][Full Text] [Related]
32. Mutational analysis of the PTPN11 gene in Egyptian patients with Noonan syndrome.
Essawi ML; Ismail MF; Afifi HH; Kobesiy MM; El Kotoury A; Barakat MM
J Formos Med Assoc; 2013 Nov; 112(11):707-12. PubMed ID: 24183200
[TBL] [Abstract][Full Text] [Related]
33. SHP-2 complex formation with the SHP-2 substrate-1 during C2C12 myogenesis.
Kontaridis MI; Liu X; Zhang L; Bennett AM
J Cell Sci; 2001 Jun; 114(Pt 11):2187-98. PubMed ID: 11493654
[TBL] [Abstract][Full Text] [Related]
34. Non-Lyn Src Family Kinases Activate SIRPα-SHP-1 to Inhibit PI3K-Akt2 and Dampen Proinflammatory Macrophage Polarization.
Shi L; Bian Z; Kidder K; Liang H; Liu Y
J Immunol; 2021 Sep; 207(5):1419-1427. PubMed ID: 34348974
[TBL] [Abstract][Full Text] [Related]
35. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation.
Araki T; Chan G; Newbigging S; Morikawa L; Bronson RT; Neel BG
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4736-41. PubMed ID: 19251646
[TBL] [Abstract][Full Text] [Related]
36. Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome.
Gauthier AS; Furstoss O; Araki T; Chan R; Neel BG; Kaplan DR; Miller FD
Neuron; 2007 Apr; 54(2):245-62. PubMed ID: 17442246
[TBL] [Abstract][Full Text] [Related]
37. A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype.
Edwards JJ; Martinelli S; Pannone L; Lo IF; Shi L; Edelmann L; Tartaglia M; Luk HM; Gelb BD
Am J Med Genet A; 2014 Sep; 164A(9):2351-5. PubMed ID: 24891296
[TBL] [Abstract][Full Text] [Related]
38. Lack of SIRPα phosphorylation and concomitantly reduced SHP-2-PI3K-Akt2 signaling decrease osteoblast differentiation.
Holm CK; Engman S; Sulniute R; Matozaki T; Oldenborg PA; Lundberg P
Biochem Biophys Res Commun; 2016 Sep; 478(1):268-273. PubMed ID: 27422603
[TBL] [Abstract][Full Text] [Related]
39. The Shp-2 tyrosine phosphatase has opposite effects in mediating the activation of extracellular signal-regulated and c-Jun NH2-terminal mitogen-activated protein kinases.
Shi ZQ; Lu W; Feng GS
J Biol Chem; 1998 Feb; 273(9):4904-8. PubMed ID: 9478933
[TBL] [Abstract][Full Text] [Related]
40. Role of SHP-2 in fibroblast growth factor receptor-mediated suppression of myogenesis in C2C12 myoblasts.
Kontaridis MI; Liu X; Zhang L; Bennett AM
Mol Cell Biol; 2002 Jun; 22(11):3875-91. PubMed ID: 11997521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
